Fly News Breaks for March 3, 2015
BSX
Mar 3, 2015 | 07:56 EDT
JPMorgan says Boston Scientific (BSX) remains a top pick after the company acquired American Medical Systems' urology portfolio from Endo (ENDP). The firm expects the deal to be 4.2% accretive in 2016, and rising to 5.4% and 6.1% accretive in 2017 and 2018. It raised its price target for Boston Scientific shares to $19 from $18 and keeps an Overweight rating on the name.
News For BSX From the Last 2 Days
There are no results for your query BSX